[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"botulinium-toxin-a\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:botulinium-toxin-a":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,53],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":5},"100640078","comparative-evaluation-of-intraneuroma-and-perineuroma-botulinum-toxin-type-a-injection-techniques-for-chronic-neuroma-pain-after-combat-related-amputation-100640078",false,"NCT07624877","Comparative Evaluation of Intraneuroma and Perineuroma Botulinum Toxin Type A Injection Techniques for Chronic Neuroma Pain After Combat-Related Amputation","Comparative Evaluation of Intraneuroma and Perineuroma Botulinum Toxin Type A Injection Techniques for Chronic Neuroma Pain After Combat-Related Amputation: A Prospective Multicenter Study","IN-PERI NEUROM","Inclusion Criteria:\n\n* Age ≥18 years\n* Combat-related limb amputation\n* Chronic neuroma pain lasting ≥3 months\n* Ultrasound-confirmed painful neuroma\n* Average neuroma pain intensity ≥4\u002F10 on the Numeric Rating Scale\n* Ability to undergo ultrasound-guided injection\n* Stable analgesic regimen for at least 14 days before enrollment\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Active infection at or near the injection site\n* Open wound preventing safe injection\n* Previous botulinum toxin injection for neuroma pain within 6 months\n* Previous neuroma surgery within 3 months\n* Known allergy to botulinum toxin type A\n* Coagulopathy or anticoagulation contraindicating injection\n* Severe uncontrolled systemic disease\n* Inability to complete follow-up assessments","ALL","18 Years","60 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"NA","Patients with combat-related amputations frequently experience chronic neuroma pain that may interfere with rehabilitation, prosthesis use, mobility, sleep, and quality of life. Ultrasound-guided botulinum toxin type A injection has emerged as a potential treatment option for persistent neuroma pain; however, the optimal injection technique remains unclear.\n\nThis prospective multicenter study aims to compare two ultrasound-guided botulinum toxin injection techniques for chronic neuroma pain after combat-related amputation: intraneuroma injection and perineuroma injection.\n\nParticipants with ultrasound-confirmed painful neuromas will undergo one of the two injection approaches based on the treating physician's clinical decision and local practice. Pain intensity, neuropathic pain characteristics, phantom limb pain, prosthesis tolerance, functional outcomes, and adverse events will be evaluated during follow-up.\n\nThe goal of the study is to evaluate the feasibility, safety, and potential clinical effectiveness of intraneuroma and perineuroma botulinum toxin type A injection techniques in patients with chronic neuroma pain following combat-related amputation.",[28,29,30,31],"Chronic Pain","Neuroma","Botulinium Toxin-A","Combat Trauma",[33,34,35,36,37,38,39,40],"Chronic neuroma pain","Combat-related amputation","Botulinum toxin type A","Intraneuroma injection","Perineuroma injection","Ultrasound-guided injection","Residual limb pain","Painful neuroma","NOT_YET_RECRUITING","2026-05-30",{"date":44,"type":45},"2026-06-03","ACTUAL",{"date":47,"type":22},"2026-05-27",{"date":49,"type":22},"2026-12-15",{"name":51,"class":52},"Ukrainian Society of Regional Anesthesia and Pain Therapy","OTHER",{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":62,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":79},"100633191","local-injection-of-botulinium-toxin-a-in-children-with-dysfunctional-voiding-or-refractory-nocturnal-eneuresis-100633191","NCT07523477","Local Injection of Botulinium Toxin-A in Children With Dysfunctional Voiding or Refractory Nocturnal Eneuresis","Evaluation of Local Injection of Botulinium Toxin-A in Children With Dysfunctional Voiding or Refractory Nocturnal Eneuresis","Inclusion Criteria:\n\n* Children \\\u003C 18 years.\n* Both sexes.\n* Patients with refractory nocturnal enuresis or dysfunctional voiding who are not responding to the traditional treatment.\n\nExclusion Criteria:\n\n* Bleeding disorders.\n* Neuromusclar disorder(e.g.,Myasthenia gravis).\n* Patients who are not fit for anaesthesia.\n* Active urinary tract infection (UTI).",{"count":61,"type":22},64,[25],"The aim of this study is to evaluate the outcome of botulinum toxin A (BTX-A) injection for management of children with :\n\nA-Dysfunctional voiding who are not responding to traditional treatment. B-Refractory nocturnal enuresis.",[65,30,66,67,68],"Local Injection","Children","Dysfunctional Voiding","Refractory Nocturnal Eneuresis","RECRUITING","2026-04-05",{"date":72,"type":45},"2026-04-13",{"date":74,"type":45},"2025-06-01",{"date":76,"type":22},"2026-12-01",{"name":78,"class":52},"Tanta University",1]